Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Early Clues to Diabetic Kidney Disease

By HospiMedica staff writers
Posted on 31 Mar 2008
A new study has found that for patients with type I diabetes, increased levels of uric acid in the blood may be an early sign of diabetic kidney disease, appearing before any significant change in urine albumin level, the standard screening test.

Researchers at the Joslin Diabetes Center (Boston, MA, USA) measured serum uric acid concentration in 675 patients with type I diabetes. More...
A medical history and measurements of blood pressure (BP), hemoglobin A1c, albumin excretion rate, and serum concentrations of uric acid and cystatin C were obtained; estimated glomerular filtration rate (GFR) was measured by a cystatin C-based formula.

On screening tests, results showed 311 patients had small amounts of the protein albumin--called microalbuminuria--in the urine. The other 364 patients had normal urine albumin levels. None of the patients had even higher levels of albumin (albuminuria), representing more advanced diabetic nephropathy; in contrast, the serum uric acid level was consistently related to kidney function--the higher the uric acid, the lower the kidney function--and one in five had some impairment of kidney function on a standard GFR test. In univariate and multivariate analyses, lower GFR was strongly and independently associated with higher serum uric acid and higher urinary albumin excretion rate, older age, and antihypertensive treatment. The study was published online ahead of print on February 13, 2008, in the Clinical Journal of the American Society of Nephrology.

"The serum uric acid concentration is modifiable by drugs or by decreasing the intake of dietary protein, the main source of uric acid,” said lead author Elizabeth Rosolowsky, M.D. "If follow-up studies, already underway, demonstrate that serum uric acid concentration predicts the course of early decline in kidney function, then clinical trials would be justified to test whether modifying serum uric acid concentration also modifies the course of renal function decline in type I diabetic patients with high normoalbuminuria or microalbuminuria.”

The association between high serum uric acid and insulin resistance has been known since the early part of the 20th century. Nevertheless, recognition of high serum uric acid as a risk factor for diabetes has been a matter of debate. In fact, hyperuricemia has always been presumed to be a consequence of insulin resistance rather than its precursor. On the other hand, it has been shown that high serum uric acid is associated with higher risk of type II diabetes independent of obesity, dyslipidemia, and hypertension.


Related Links:
Joslin Diabetes Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.